Squarepoint
PRAX icon

Squarepoint’s Praxis Precision Medicines PRAX Stock Holding History

Squarepoint’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2M Buy
42,501
+40,491
+2,014% +$12.8M 0.02% 873
2026
Q1 		$648K Buy
2,010
+120
+6% +$37.1K ﹤0.01% 3125
2025
Q4 		$557K Buy
+1,890
New +$352K ﹤0.01% 3122
2025
Q1 		– Sell
-7,782
Closed -$599K – 5228
2024
Q4 		$599K Sell
7,782
-6,876
-47% -$498K ﹤0.01% 3578
2024
Q3 		$843K Buy
14,658
+1,310
+10% +$70.8K ﹤0.01% 2728
2024
Q2 		$552K Buy
13,348
+6,942
+108% +$328K ﹤0.01% 3003
2024
Q1 		$391K Buy
+6,406
New +$287K ﹤0.01% 3215
2023
Q2 		– Sell
-3,102
Closed -$37.6K – 3909
2023
Q1 		$37.6K Buy
3,102
+1,394
+82% +$58.8K ﹤0.01% 3080
2022
Q4 		$61K Sell
1,708
-10,106
-86% -$315K ﹤0.01% 3033
2022
Q3 		$402K Buy
11,814
+10,377
+722% +$517K ﹤0.01% 2312
2022
Q2 		$53K Buy
+1,437
New +$153K ﹤0.01% 2701
2021
Q3 		– Sell
-1,162
Closed -$319K – 3322
2021
Q2 		$319K Buy
+1,162
New +$416K ﹤0.01% 2481

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Squarepoint's PRAX Position: Q2 2026 in Review

Squarepoint increased its Praxis Precision Medicines (PRAX) stake by 2,014% in Q2 2026, buying an estimated $12.8M and bringing the position to 42,501 shares worth $14.2M. The position accounts for 0.02% of the portfolio, ranked #873.

Squarepoint first reported a position in PRAX in Q2 2021 and has held it in 12 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Squarepoint held 42,501 shares of Praxis Precision Medicines worth $14.2M as of Q2 2026.
  • Squarepoint bought 40,491 Praxis Precision Medicines shares in Q2 2026, an estimated $12.8M.
  • Praxis Precision Medicines made up 0.02% of Squarepoint's portfolio in Q2 2026, its #873 holding.
  • Squarepoint first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 12 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.